Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.
Standard
Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. / Tallen, Gesche; Ratei, Richard; Mann, Georg; Kaspers, Gertjan; Niggli, Felix; Karachunsky, Alexandr; Ebell, Wolfram; Escherich, Gabriele; Schrappe, Martin; Klingebiel, Thomas; Fengler, Ruediger; Henze, Günter; von Stackelberg, Arend.
In: J CLIN ONCOL, Vol. 28, No. 14, 14, 2010, p. 2339-2347.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.
AU - Tallen, Gesche
AU - Ratei, Richard
AU - Mann, Georg
AU - Kaspers, Gertjan
AU - Niggli, Felix
AU - Karachunsky, Alexandr
AU - Ebell, Wolfram
AU - Escherich, Gabriele
AU - Schrappe, Martin
AU - Klingebiel, Thomas
AU - Fengler, Ruediger
AU - Henze, Günter
AU - von Stackelberg, Arend
PY - 2010
Y1 - 2010
N2 - The multicenter trial ALL-REZ BFM (ie, Acute Lymphoblastic Leukemia Relapse Berlin-Frankfurt-Münster) 90 was designed to improve prognosis for children with relapsed acute lymphoblastic leukemia (ALL) by time-to-relapse- and site-of-relapse-adapted stratification and by introduction of novel chemotherapy elements and to evaluate new prognostic parameters in a large, population-based cohort.
AB - The multicenter trial ALL-REZ BFM (ie, Acute Lymphoblastic Leukemia Relapse Berlin-Frankfurt-Münster) 90 was designed to improve prognosis for children with relapsed acute lymphoblastic leukemia (ALL) by time-to-relapse- and site-of-relapse-adapted stratification and by introduction of novel chemotherapy elements and to evaluate new prognostic parameters in a large, population-based cohort.
KW - Humans
KW - Male
KW - Female
KW - Risk Factors
KW - Adolescent
KW - Treatment Outcome
KW - Europe
KW - dosage
KW - Child
KW - Risk Assessment
KW - Time Factors
KW - Disease-Free Survival
KW - Proportional Hazards Models
KW - Child, Preschool
KW - Antineoplastic Combined Chemotherapy Protocols therapeutic use
KW - Etoposide administration
KW - Recurrence
KW - Chi-Square Distribution
KW - Stem Cell Transplantation
KW - Cranial Irradiation
KW - Cytarabine administration
KW - Drug Administration Schedule
KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy
KW - Radiotherapy, Adjuvant
KW - Humans
KW - Male
KW - Female
KW - Risk Factors
KW - Adolescent
KW - Treatment Outcome
KW - Europe
KW - dosage
KW - Child
KW - Risk Assessment
KW - Time Factors
KW - Disease-Free Survival
KW - Proportional Hazards Models
KW - Child, Preschool
KW - Antineoplastic Combined Chemotherapy Protocols therapeutic use
KW - Etoposide administration
KW - Recurrence
KW - Chi-Square Distribution
KW - Stem Cell Transplantation
KW - Cranial Irradiation
KW - Cytarabine administration
KW - Drug Administration Schedule
KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy
KW - Radiotherapy, Adjuvant
M3 - SCORING: Zeitschriftenaufsatz
VL - 28
SP - 2339
EP - 2347
JO - J CLIN ONCOL
JF - J CLIN ONCOL
SN - 0732-183X
IS - 14
M1 - 14
ER -